Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain: The Case of the Sigma-1 Receptor
- PMID: 35434530
- PMCID: PMC9003638
- DOI: 10.1021/acsptsci.2c00005
Comprehensive Preclinical Assessment of Sensory, Functional, Motivational-Affective, and Neurochemical Outcomes in Neuropathic Pain: The Case of the Sigma-1 Receptor
Abstract
Chronic pain remains a major health problem and is currently facing slow drug innovation. New drug treatments should address not only the sensory-discriminative but also functional and motivational-affective components of chronic pain. In a mouse model of neuropathic pain induced by partial sciatic nerve ligation (PSNL), we analyzed sensory and functional-like outcomes by hindpaw mechanical stimulation and automated gait analysis (CatWalk). We characterized over time a reward-seeking task based on diminished motivation for natural reinforcers (anhedonic-like behavior). To differentiate the appetitive ("wanting") and consummatory ("liking") aspects of motivational behavior, we quantified the latency and number of approaches to eat white chocolate, as well as the eating duration and amount consumed. We explored a putative chronic pain-induced dysregulation of monoamine function by measuring monoamine levels in the nucleus accumbens (NAc), a well-known brain reward area. Finally, we investigated the role of sigma-1 receptor (σ1R) modulation, a nonopioid target, in these multiple dimensions by genetic deletion and pharmacological dose-response studies. After 6 weeks, PSNL increased the approach latency and reduced the consumption of white chocolate in 20-25% of the mice, while around 50-60% had one or the other parameter affected independently. After 10 weeks, sham-operated mice also displayed anhedonic-like behavior. PSNL was associated with reduced extracellular baseline dopamine and increased norepinephrine in the NAc and with a suppression of increased dopamine and serotonin efflux in response to the rewarding stimulus. Genetic and pharmacological blockade of σ1R relieved these multiple alterations in nerve-injured mice. We comprehensively describe sensory, functional, and depression-like impairment of key components of motivated behavior associated with nerve injury. We provide a neurochemical substrate for the depressed mesocorticolimbic reward processing in chronic pain, with a potentially increased translational value. Our results also highlight σ1R for the therapeutic intervention of neuropathic pain.
© 2022 American Chemical Society.
Conflict of interest statement
The authors declare the following competing financial interest(s): All authors are currently full-time employees of Welab Barcelona and formerly full-time employees of ESTEVE Pharmaceuticals, when the experimental work was performed.
Figures




Similar articles
-
Resilience to Pain-Related Depression in σ1 Receptor Knockout Mice Is Associated with the Reversal of Pain-Induced Brain Changes in Affect-Related Genes.ACS Chem Neurosci. 2023 Oct 4;14(19):3714-3725. doi: 10.1021/acschemneuro.3c00502. Epub 2023 Sep 22. ACS Chem Neurosci. 2023. PMID: 37738096
-
Behavioral and receptor expression studies on the primary somatosensory cortex and anterior cingulate cortex oxytocin involvement in modulation of sensory and affective dimensions of neuropathic pain induced by partial sciatic nerve ligation in rats.Physiol Behav. 2022 Jul 1;251:113818. doi: 10.1016/j.physbeh.2022.113818. Epub 2022 Apr 17. Physiol Behav. 2022. PMID: 35443199
-
Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice.Mol Pain. 2014 Feb 11;10:11. doi: 10.1186/1744-8069-10-11. Mol Pain. 2014. PMID: 24517272 Free PMC article.
-
Lateral hypothalamus, nucleus accumbens, and ventral pallidum roles in eating and hunger: interactions between homeostatic and reward circuitry.Front Syst Neurosci. 2015 Jun 15;9:90. doi: 10.3389/fnsys.2015.00090. eCollection 2015. Front Syst Neurosci. 2015. PMID: 26124708 Free PMC article. Review.
-
Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain.Adv Exp Med Biol. 2017;964:85-107. doi: 10.1007/978-3-319-50174-1_8. Adv Exp Med Biol. 2017. PMID: 28315267 Review.
Cited by
-
Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.Sci Rep. 2022 Jun 12;12(1):9719. doi: 10.1038/s41598-022-13968-7. Sci Rep. 2022. PMID: 35691979 Free PMC article.
-
Long-Lasting Nociplastic Pain Modulation by Repeated Administration of Sigma-1 Receptor Antagonist BD1063 in Fibromyalgia-like Mouse Models.Int J Mol Sci. 2022 Oct 8;23(19):11933. doi: 10.3390/ijms231911933. Int J Mol Sci. 2022. PMID: 36233233 Free PMC article.
-
Miyako Bidens pilosa Extract Ameliorates Allodynia and Suppresses Spinal Microglial Activation in Mice with Partial Sciatic Nerve Ligation.Curr Issues Mol Biol. 2025 Jun 12;47(6):453. doi: 10.3390/cimb47060453. Curr Issues Mol Biol. 2025. PMID: 40699852 Free PMC article.
-
Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.Pharmaceuticals (Basel). 2023 Jul 5;16(7):962. doi: 10.3390/ph16070962. Pharmaceuticals (Basel). 2023. PMID: 37513874 Free PMC article.
-
Sphingoid Bases Regulate the Sigma-1 Receptor-Sphingosine and N,N'-Dimethylsphingosine Are Endogenous Agonists.Int J Mol Sci. 2023 Feb 4;24(4):3103. doi: 10.3390/ijms24043103. Int J Mol Sci. 2023. PMID: 36834510 Free PMC article.
References
-
- Treede R.-D.; Rief W.; Barke A.; Aziz Q.; Bennett M. I.; Benoliel R.; Cohen M.; Evers S.; Finnerup N. B.; First M. B.; Giamberardino M. A.; Kaasa S.; Korwisi B.; Kosek E.; Lavand’homme P.; Nicholas M.; Perrot S.; Scholz J.; Schug S.; Smith B. H.; Svensson P.; Vlaeyen J. W. S.; Wang S.-J. Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019, 160, 19–27. 10.1097/j.pain.0000000000001384. - DOI - PubMed
-
- Busse J. W.; Wang L.; Kamaleldin M.; Craigie S.; Riva J. J.; Montoya L.; Mulla S. M.; Lopes L. C.; Vogel N.; Chen E.; Kirmayr K.; De Oliveira K.; Olivieri L.; Kaushal A.; Chaparro L. E.; Oyberman I.; Agarwal A.; Couban R.; Tsoi L.; Lam T.; Vandvik P. O.; Hsu S.; Bala M. M.; Schandelmaier S.; Scheidecker A.; Ebrahim S.; Ashoorion V.; Rehman Y.; Hong P. J.; Ross S.; Johnston B. C.; Kunz R.; Sun X.; Buckley N.; Sessler D. I.; Guyatt G. H. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. JAMA 2018, 320, 2448.10.1001/jama.2018.18472. - DOI - PMC - PubMed
-
- Kleykamp B. A.; Ferguson M. C.; McNicol E.; Bixho I.; Arnold L. M.; Edwards R. R.; Fillingim R.; Grol-Prokopczyk H.; Turk D. C.; Dworkin R. H. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: An ACTTION Systematic Review. Semin. Arthritis Rheum. 2021, 51, 166–174. 10.1016/j.semarthrit.2020.10.006. - DOI - PubMed
LinkOut - more resources
Full Text Sources